{
 "drug": "Tafamidis Meglumine Capsule",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "09/29/2025",
 "dayN": 330,
 "cat": "Cardiovascular",
 "companies": [
  "Pfizer Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "09/29/2025",
   "update_type": "New",
   "initial_posting_date": "09/29/2025",
   "package_ndc": "0069-1975-40",
   "generic_name": "Tafamidis Meglumine Capsule",
   "contact_info": "800-879-3477",
   "related_info": "Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.",
   "openfda": {
    "application_number": [
     "NDA211996"
    ],
    "brand_name": [
     "VYNDAQEL"
    ],
    "generic_name": [
     "TAFAMIDIS MEGLUMINE"
    ],
    "manufacturer_name": [
     "Pfizer Laboratories Div Pfizer Inc"
    ],
    "product_ndc": [
     "0069-1975",
     "0069-8730"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "TAFAMIDIS MEGLUMINE"
    ],
    "rxcui": [
     "2168534",
     "2168540",
     "2168542",
     "2168548"
    ],
    "spl_id": [
     "67f1031d-c298-4cf9-9051-bb8f99e56442"
    ],
    "spl_set_id": [
     "1b4121ee-a733-4456-a917-be2603477839"
    ],
    "package_ndc": [
     "0069-1975-12",
     "0069-1975-40",
     "0069-8730-01",
     "0069-8730-30"
    ],
    "unii": [
     "ZU7CF08A1A",
     "8FG9H9D31J"
    ]
   },
   "update_date": "09/29/2025",
   "therapeutic_category": [
    "Cardiovascular"
   ],
   "dosage_form": "Capsule",
   "presentation": "Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  }
 ]
}